SECsense Logo

ADMA Biologics 8-K Report: Key Updates and Financial Insights - December 2024

$ADMA
Form 8-K
Filed on: 2024-12-20
Source
ADMA Biologics 8-K Report: Key Updates and Financial Insights - December 2024

The provided section of the financial report contains key information about ADMA Biologics, Inc. from an SEC filing. Here are the most important details extracted from the text:

  1. Entity Information:
  • Company Name: ADMA Biologics, Inc.
  • CIK Number: 0001368514
  • State of Incorporation: Delaware (DE)
  • SEC File Number: 001-36728
  • EIN: 56-2590442
  • Address: 465 State Route 17, Ramsey, NJ 07446
  • Phone Number: 201-478-5552
  1. Filing Details:
  • Filing Type: 8-K (Current Report)
  • Filing Date: December 20, 2024
  1. Financial Instruments:
  • Common Stock: The report pertains to the common stock of ADMA Biologics, which is traded on NASDAQ under the ticker symbol "ADMA".
  1. Reporting Period:
  • Start Date: December 20, 2024
  • End Date: December 20, 2024
  • This indicates that the filing may relate to a specific event or development occurring on that date.
  1. XBRL Information:
  • The document is structured in XML-based XBRL format, which facilitates the electronic filing and analysis of financial reports.

Insights:

  • The filing is a Form 8-K, which typically reports unscheduled material events or corporate changes that are important to shareholders.
  • The date of the report and the short reporting period suggest that it may relate to a specific significant event or announcement by the company on that day.
  • The mention of common stock indicates that this filing could impact shareholders and potential investors looking to assess the company's performance or future prospects.

This information can be critical for investors, analysts, and regulators who need to understand the company's current status and any recent developments that may affect its financial health or stock performance.